Researchers have discovered an antibody able to neutralize all known variants of SARS-CoV-2, the virus that causes COVID-19, as well as similar coronaviruses.

Protein large language models identify ways to make antibiotics better at targeting dangerous bacteria, without being toxic to humans.

An innovative approach uses artificial intelligence and biosensors to pave the way for faster drug development.

Yi Lu and Lauren Ehrlich of the College of Natural Sciences are among the cancer researchers with exciting projects on the horizon.

Bacteria use iron levels to store memories and pass them on to later generations, scientists have found.

A team led by Lauren Ehrlich found a link between myeloid cells and the cancer that often strikes children.

Drug candidate developed by Everett Stone and his team is effective in mice with cancers of skin, bladder, blood and colon.

Every year, millions of people become sickened by RSV, and more than 100,000 die. New vaccines with a connection to UT Austin may help turn those numbers around.

A biologist at UT Austin who played a key role in the development of COVID-19 and RSV vaccines has received honors for the far-reaching impact of his research.

Alone, this target might not be strong enough to directly block infection, but might be used to jump-start or boost an immune response.